Lung nodule diagnosis and cancer histology classification from computed tomography data by convolutional neural networks: A survey.
Selene Tomassini, Nicola Falcionelli, Paolo Sernani...
https://pubmed.ncbi.nlm.nih.gov/35691714/Actively Recruiting
Led by Università degli Studi di Trento · Updated on 2026-07-14
700
Participants Needed
1
Research Sites
208 weeks
Total Duration
The GLIOMAID project focuses on improving diagnosis and management of brain tumors called gliomas using Artificial Intelligence AI. Gliomas, especially high-grade types, are common and challenging brain tumors with poor survival rates, often requiring invasive biopsies. This study aims to create AI tools that analyze MRI scans and patient data to help doctors detect tumors earlier, understand their severity, and plan better treatments without invasive procedures. The study collects existing clinical and MRI data from about 700 adult glioma patients aged 18 to 60, treated between 2019 and 2024 at seven neurosurgery centers in Italy. It uses AI algorithms to analyze these retrospective records to develop models for early tumor detection, automated tumor mapping on MRI images, and non-invasive tumor characterization. No new treatments or interventions are given during the study. Participants data includes pre- and post-operative MRI scans and clinical information such as diagnosis, treatment history, and outcomes. All data is anonymized and securely stored. Researchers evaluate the accuracy of AI models in detecting and classifying gliomas compared to expert reviews and histological diagnoses. The study aims to support faster, more accurate diagnosis and personalized treatment planning while reducing the need for invasive biopsies.
CONDITIONS
AI-driven Processing and Analysis of Glioma Imaging Data
S
Silvio Sarubbo, MD Spec., PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Università degli Studi di Trento
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (remote or in-person)
Duration - Up to 24 months
Participants' existing MRI scans and clinical data are collected and analyzed using AI tools to develop models for glioma detection, tumor mapping, and characterization. No new treatments or procedures are given.
No visits required during this stage
Duration - Up to 36 months
Researchers review and validate the AI model results by comparing them with expert evaluations and biopsy findings. There is no direct participant involvement during this stage.
No visits required
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Selene Tomassini, Nicola Falcionelli, Paolo Sernani...
https://pubmed.ncbi.nlm.nih.gov/35691714/Tamara Ius, Fabrizio Pignotti, Giuseppe Maria Della Pepa...
https://pubmed.ncbi.nlm.nih.gov/32046132/Luca Zigiotto, Luciano Annicchiarico, Francesco Corsini...
https://pubmed.ncbi.nlm.nih.gov/32303975/Laurent Capelle, Denys Fontaine, Emmanuel Mandonnet...
https://pubmed.ncbi.nlm.nih.gov/23495881/Hiroko Ohgaki
https://pubmed.ncbi.nlm.nih.gov/19107440/Roger Stupp, Warren P Mason, Martin J van den Bent...
https://pubmed.ncbi.nlm.nih.gov/15758009/P D Delgado-López, E M Corrales-García
https://pubmed.ncbi.nlm.nih.gov/26960561/S Suganyadevi, V Seethalakshmi, K Balasamy
https://pubmed.ncbi.nlm.nih.gov/34513553/Nader Sanai, Mitchel S Berger
https://pubmed.ncbi.nlm.nih.gov/18496181/Jean-Michel Lemée, Anne Clavreul, Philippe Menei
https://pubmed.ncbi.nlm.nih.gov/26203067/Università degli Studi di Trento
Lead Sponsor